LIBTAYO works with your immune system to help treat the following types of cancer:

LIBTAYO is approved for people with a type of lung cancer called non–small cell lung cancer (NSCLC). LIBTAYO may be used as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high "PD-L1," and your tumor does not have an abnormal "EGFR," "ALK," or "ROS1" gene

Now Approved IN

Advanced NSCLC

Learn more Patient portrayal.

LIBTAYO is approved for people with a type of skin cancer called basal cell carcinoma (BCC) that cannot be removed by surgery (locally advanced BCC) and who have received treatment with a hedgehog inhibitor (HHI), or cannot receive treatment with an HHI

Now Approved IN

Locally
Advanced BCC

Learn more Patient portrayal.

The first treatment approved for people with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation

APPROVED IN 2018 FOR

Advanced CSCC

Learn more Actual LIBTAYO patient.